Savage et al reported prognostic factors for patients with an ALK-positive (ALK+) anaplastic large-cell lymphoma (ALCL) These can help to identify a patient who may benefit from more aggressive management. The authors are from institutions around the world participating in the International Peripheral T-Cell Lymphoma Project.
Outcomes: overall survival and failure-free survival (FFS)
Parameters:
(1) age
(2) performance score
(3) clinical stage
(4) serum LDH
(5) number of extranodal sites
(6) hemoglobin in g/L
Parameter |
Finding |
Points |
age |
<= 60 years of age |
0 |
|
> 60 years of age |
1 |
performance scale |
0 to 2 |
0 |
|
3 or 4 |
1 |
clinical stage |
I or II |
0 |
|
III |
1 |
|
IV |
2 |
serum LDH |
normal |
0 |
|
elevated |
1 |
number of extranodal sites |
0 or 1 |
0 |
|
2 or more |
1 |
hemoglobin |
>= 110 g/L |
0 |
|
< 110 g/L |
1 |
total number of adverse prognostic factors =
= SUM(points for all 6 prognostic factors)
Interpretation:
• minimum number of adverse prognostic factors: 0
• maximum number of adverse prognostic factors: 6
• The outcome is worse as the number of adverse prognostic factors increase.
Specialty: Hematology Oncology